But now for the Good news: Can-C is the real alternative to cataract surgery!

What is Can-C?

Can-C is a non-invasive, anti-oxidant eye drop - the only cataract eye drop proven in clinical trials to be effective in the treatment of cataracts and safe for long-term use. Approved and patented by Innovative Vision Products, who developed the technology behind this breakthrough in cataract treatment, Can-C contains N-acetylcarnosine a natural and powerful anti-oxidant.

While there are other commercially available N-acetylcarnosine eye-drops, some contain chemicals which should not be applied directly to the eye. Can-C is the only original, high purity, tested and approved brand that is safe for use in your eyes.

How does Can-C work?

The reason that Can-C is so effective in the treatment of cataracts lies in its use of N-acetylcarnosine. Some of the most significant research in this field has been spear- headed by Dr Mark Babizhayev, based at the Moscow Helmholtz Research Institute of Eye Diseases and the driving force behind Innovative Vision Products. The breakthrough came when researchers were able to demonstrate, in human trials, that “the N-acetylated form of natural dipeptide L-carnosine appears to be suitable and physiologically acceptable for nonsurgical treatment for senile cataracts.”7

For example in one study8, researchers evaluated the effects of 1% N-acetylcarnosine solution on lens clarity over 6 and 24 months in patients. Forty nine patients with of an average age of 65 and with a total of 76 eyes affected by senile cataracts were recruited to the study. Twenty six patients (41 affected eyes) were given topical 1% N-acetylcarnosine eyedrops twice daily. The control group consisted of thirteen patients (21 eyes) and they received placebo eyedrops. Ten patients (14 eyes) did not receive eyedrops at all. All the patients were evaluated at the start of the trial for best-corrected visual acuity and glare testing. They were then either followed up every 2 months for a 6-month period (trial 1), or at 6-month intervals for a 2-year period (trial 2). In addition, cataracts were measured using stereocinematographic slit-images and retro-illumination examination of the lens.

After only 6 months of using the eyedrops twice daily, researchers found that an incredible 90% of the treated eyes showed an improvement in best corrected visual acuity (7 to 100%), 88.9% showed a 27 to 100% improvement in glare sensitivity and 41.5% of the treated eyes also had improvement in image analysis characteristics.

The apparent benefits of treatment were sustained even after 24 months' treatment and with none of the treated eyes displaying any worsening of vision. By contrast, the overall visual outcome in the control group showed significant worsening after 24 months when compared with the results of both their baseline and 6-month follow-up examinations.

Possibly as exciting as the amazing improvements demonstrated in those treated with 1% N-acetylcarnosine, was the fact that tolerance to the eyedrops was good in almost all patients, with no reports of any adverse side effects. It is hardly surprising therefore that the researchers concluded that topical 1% N-acetylcarnosine showed “potential for the treatment and prevention of cataracts.” 8

Dr Babizhayev and his team also investigated the use of N-acetylcarnosine eyedrops with people who did not yet have the symptoms of cataracts, but who had varying degrees of visual impairment.9 In this study, the participants were aged between 48 and 60 years and used the eyedrops for a course of treatment ranging from 2 to 6 months. The participants reported that the eyedrops “brightened” and “relaxed” their eyes, with the eyedrops alleviating eye tiredness and providing participants with improved, clearer vision. The importance of this piece of research lies in the fact that it indicates that the eyedrops have a value not only for preventive purposes but also a medical application by way of therapy.

What is N-acetylcarnosine?

N-acetylcarnosine is a form of carnosine. Carnosine is a small molecule (a di-peptide) composed of the amino acids histidine and alanine. It is a naturally occurring substance in the body and is found in relatively high concentrations in several body tissues—most notably in skeletal muscle, heart muscle, nerve tissue and brain. Extensive research has shown that carnosine is important for preventing glycation - one of the root causes in the formation of senile cataracts. It is capable of slowing and helping to stop the cross linking of proteins.

Carnosine is also an excellent anti-oxidant, capable of providing protection against free radical damage – again something that has been implicated heavily in the development of cataracts. Unfortunately as we get older our carnosine levels decrease, and there is a proven link between this decline and the onset of certain aging disorders, such as cataracts.

Researchers have found that it is the N-acetylcarnosine form of carnosine that is crucial in the treatment of cataracts. N-acetylcarnosine acts as a “carrier” of carnosine, delivering it directly into the aqueous humor of the eye (the fluid surrounding the lens). N-acetylcarnosine is known to be highly resistant to carnosinase - the natural enzyme that breaks down L-carnosine into histamine etc. Indeed, when testing the use of L-carnosine as eyedrops as opposed to N-acetylcarnosine eyedrops, researchers found that there was no presence of L-carnosine in the aqueous humor (even after 30-minutes). It is thought that this is because the L-carnosine had already been broken down into it’s constituent elements of histamine etc. Administered in the form of eye drops, N-acetylcarnosine transforms into pure carnosine once inside the eye, making it a natural and powerful anti-oxidant.

Not only is N-acetylcarnosine capable of slowing down and preventing the development of cataracts, it is also capable of reversing existing damage.

Before the development of N-acetylcarnosine eye drops, the best that could be hoped for would be a slowing of the disorder. Now, at last, there is a viable alternative to surgery.

How effective is Can-C?

Statistics from trials show that Can-C eye-drops, applied for six months twice daily into the eye, in patients suffering from cataracts resulted in the following:

Is Can-C beneficial for anything else?

In addition to the proven results Can-C eye drops have demonstrated in treating cataracts, there are further potential benefits. Although the information is not yet published, Can-C is believed to have a positive effect on other eye disorders, such as:

What is the dosage?

N-acetylcarnosine eye drops have been shown to have measurable affects within just one month of use. To achieve the best results, however, it is recommended you continue using them for a period of not less than three to five months. The sooner you start taking them after detecting a cataract, the better.

As a preventative measure, take two drops in both eyes once a day. As a treatment, two drops into the affected eye twice daily is the ideal regime. There is no benefit in exceeding this dose. You can continue to use N-acetylcarnosine eye drops occasionally even after treatment has been successful to prevent any re-occurrence.

Are there any side effects?

No serious side effects or contraindications have been reported in trials of N-acetylcarnosine. Stinging is a very rare side effect which some people may experience. Can-C is formulated to a Ph of 6.8, which is normal for the average person, but some individuals – either due to a medical condition or diet – may have a more acidic or alkaline balance in their body, which can cause stinging.

Any stinging should naturally disappear with continued use, but if it is too uncomfortable Can-C use should be stopped.

If you are using other prescription eye drop medications, we recommend you seek guidance from your ophthalmic physician before using Can-C.


CataractEyeDrop.com want to provide you with all the information so you can make an informed decision.

Back to Top